Pembrolizumab (Keytruda) combined with trastuzumab (Herceptin) and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer, according to findings from a phase 2 trial published in the Lancet Oncology.
https://www.oncnursingnews.com/web-exclusives/immunotherapybased-triplet-is-active-in-her2-esophagogastric-cancer